A detailed history of Arizona State Retirement System transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Arizona State Retirement System holds 5,039 shares of KRYS stock, worth $928,889. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,039
Previous 5,087 0.94%
Holding current value
$928,889
Previous $631,000 42.0%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$108.01 - $179.35 $5,184 - $8,608
-48 Reduced 0.94%
5,039 $896,000
Q4 2023

Jan 24, 2024

SELL
$96.0 - $128.29 $864 - $1,154
-9 Reduced 0.18%
5,087 $631,000
Q3 2023

Nov 06, 2023

SELL
$108.51 - $130.22 $36,459 - $43,753
-336 Reduced 6.19%
5,096 $591,000
Q2 2023

Aug 01, 2023

BUY
$78.48 - $130.32 $16,480 - $27,367
210 Added 4.02%
5,432 $637,000
Q1 2023

Apr 27, 2023

BUY
$72.39 - $84.27 $11,075 - $12,893
153 Added 3.02%
5,222 $418,000
Q4 2022

Feb 07, 2023

BUY
$63.14 - $79.9 $12,186 - $15,420
193 Added 3.96%
5,069 $401,000
Q3 2022

Nov 07, 2022

BUY
$64.85 - $82.4 $10,246 - $13,019
158 Added 3.35%
4,876 $340,000
Q2 2022

Jul 28, 2022

BUY
$48.93 - $73.47 $293 - $440
6 Added 0.13%
4,718 $310,000
Q1 2022

May 04, 2022

BUY
$51.99 - $72.11 $42,995 - $59,634
827 Added 21.29%
4,712 $314,000
Q4 2021

Feb 04, 2022

SELL
$39.81 - $88.24 $1,831 - $4,059
-46 Reduced 1.17%
3,885 $272,000
Q3 2021

Nov 12, 2021

BUY
$52.01 - $71.77 $3,016 - $4,162
58 Added 1.5%
3,931 $205,000
Q2 2021

Aug 02, 2021

BUY
$62.14 - $81.82 $8,948 - $11,782
144 Added 3.86%
3,873 $263,000
Q1 2021

May 06, 2021

BUY
$59.42 - $85.46 $1,366 - $1,965
23 Added 0.62%
3,729 $287,000
Q4 2020

Jan 28, 2021

BUY
$40.64 - $61.38 $150,611 - $227,474
3,706 New
3,706 $222,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.73B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.